Group 1 - The report outlines the "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)", which sets a roadmap for the future development of the traditional Chinese medicine (TCM) industry, emphasizing the promotion of national medicines and famous products [3][12][13] - The core goal by 2030 is to establish a collaborative system across the entire industry chain, enhance the supply of raw materials, and significantly improve the levels of digitalization and greening [3][13] - Specific quantitative targets include cultivating 60 high-standard raw material bases, establishing 5 innovation centers, and constructing 20 smart factories and 10 green factories [3][13][14] Group 2 - The market size for TCM products is projected to reach approximately 506.1 billion yuan in 2025, with the market for TCM raw materials expected to grow to 220.6 billion yuan [21][24][26] - The planting area for TCM materials is estimated to be around 57 million mu in 2025, indicating a steady growth trend [20][22] - The production of traditional Chinese medicine is expected to decline, with an estimated output of 1.855 million tons in 2025, down from 1.953 million tons in 2024 [28][32] Group 3 - The report identifies five companies related to the TCM industry chain listed on the Beijing Stock Exchange: Zizhong Palace, Datang Pharmaceutical, Oukan Pharmaceutical, New Ganjing, and Biological Valley [29][30] - Among the companies, Jiren Pharmaceutical is highlighted with a projected revenue of 1.23 billion yuan and a net profit of approximately 131.84 million yuan for 2024 [51] - The report notes that 52.38% of the pharmaceutical and biological stocks on the exchange experienced price increases, with TCM stocks showing a weekly increase of 4.29% [4][42]

Core Insights - The healthcare reform in Anhui province has significantly improved access to medical services, with a focus on a tiered diagnosis and treatment system that connects local patients with provincial experts [1][4] - The establishment of a comprehensive health service system for the elderly and children is progressing, with high rates of chronic disease management and a growing number of healthcare facilities [2][3] - The integration of traditional Chinese medicine into community health services is being emphasized, enhancing local healthcare offerings and promoting the preservation of traditional practices [3][4] Group 1: Healthcare Access and Reform - Anhui has launched a "three-level consultation and referral platform," allowing patients to connect with experts easily, resulting in 90% of county hospitals achieving tertiary service capabilities [1] - The province has built a network of 2,587 medical institutions for acute infectious disease monitoring, with a diagnostic report timeliness rate of over 99% [1] Group 2: Elderly and Child Health Services - The province has achieved a 96.8% rate of setting up geriatric departments in secondary and higher-level hospitals, with a total of over 80,000 medical and nursing beds available [2] - Community health services are actively managing chronic diseases, with over 75% of hypertension and diabetes patients receiving standardized management [2] Group 3: Integration of Traditional Medicine - All community health service centers and township hospitals in Anhui have established traditional Chinese medicine facilities, providing local access to services like acupuncture and massage [3] - The province is promoting the quality control of traditional medicine products through information traceability systems, enhancing the global reach of Anhui's traditional medicine brands [3]

Core Viewpoint - Jiren Pharmaceutical is shifting its IPO target to the Beijing Stock Exchange after failing in the A-share market, facing multiple challenges including high accounts receivable and inventory, declining gross margins, and governance issues due to family control [2]. Financial Performance - Jiren Pharmaceutical's revenue is projected to grow from approximately 1.024 billion yuan in 2022 to 1.23 billion yuan in 2024, but net profit is declining, with figures of 157 million yuan in 2022 dropping to 131 million yuan in both 2023 and 2024 [3]. - In the first half of 2025, revenue fell to 563 million yuan and net profit to 55 million yuan, showing significant declines compared to the same period in 2024 [3]. Cash Flow and Working Capital - The company's net cash flow from operating activities has been volatile and consistently lower than net profit, with figures dropping from 156 million yuan in 2022 to just 10 million yuan in 2024 [4]. - As of the end of 2024, accounts receivable reached 796 million yuan, accounting for 45.43% of total assets, while inventory was 267 million yuan, making up 15.24% of total assets [4]. Gross Margin Trends - Jiren Pharmaceutical's gross margin has been declining, from 51.3% in 2022 to 41.71% in 2024, with a further drop to 41.05% in the first half of 2025, indicating weakened profitability [5]. - The decline in gross margin is attributed to fluctuations in raw material prices and changes in product sales structure, with key raw materials experiencing significant price increases [5]. Product Performance and Market Challenges - The core product, Shufeng Jiedu Capsule, has seen a decline in sales from 503 million yuan in 2022 to 136 million yuan in the first half of 2025, with a 25% drop in 2024 compared to 2022 [6]. - The company is attempting to increase market share through price reductions, but the effectiveness of this strategy remains uncertain [6]. Governance and Ownership Structure - Jiren Pharmaceutical is heavily controlled by the founding family, with the controlling shareholder holding 87.06% of the shares, raising concerns about governance and decision-making transparency [9]. - The family’s involvement in management and the company's stock incentive plans reflect a governance model that may lack checks and balances, potentially affecting minority shareholders' rights [13]. Dividend Policy - Despite financial pressures, Jiren Pharmaceutical has maintained cash dividends, distributing 20 million yuan in 2021, 23 million yuan in 2022, and 25 million yuan in 2023, raising questions about the rationality of cash distribution amid declining performance [13].

Core Viewpoint - Anhui Jiren Pharmaceutical Co., Ltd. has had its IPO application accepted by the Beijing Stock Exchange, following a previous unsuccessful attempt to list on the Shanghai Stock Exchange due to unanswered inquiries [1][9]. Financial Performance - The company reported revenues of 1.025 billion yuan, 1.134 billion yuan, 1.23 billion yuan, and 837 million yuan for the years 2022 to 2025, with a decline in revenue and profit of 6.05% and 15.45% respectively in the first half of 2025 compared to the previous year [2][10]. - The revenue from traditional Chinese medicine (TCM) decoction pieces accounted for the highest proportion of income, increasing from 43.96% in 2022 to 66.61% in 2025 [2][10]. Product Dependency - The company heavily relies on its core product, the Shufeng Jiedu Capsule, which accounted for 95% of its revenue, with sales declining from 503 million yuan in 2022 to 136 million yuan in the first half of 2025 [4][12]. - The average price of the core product has also decreased, indicating a downward trend in both sales volume and pricing [4][12]. Cost Structure - The company incurred significant sales expenses, totaling 862 million yuan from 2022 to 2025, with academic promotion costs making up 72.6% of these expenses [5][13]. - Research and development (R&D) investment has been low, with only 92 million yuan spent over three and a half years, leading to a low R&D expense ratio of 2.27% in 2024 [5][13]. Ownership and Dividend Policy - The company is controlled by the family of the actual controller, Zhu Yuexin, who holds 87.06% of the shares, with the family collectively owning 99.12% [6][15]. - Despite financial pressures, the company has maintained a policy of increasing cash dividends, distributing a total of 68 million yuan over the reporting period [6][15].

新京报贝壳财经讯（记者黄鑫宇）12月26日晚，北交所官网显示，安徽济人药业股份有限公司（即"济 人药业"，874919）IPO申请获北交所受理。 2023年3月，济人药业曾向上交所主板提交IPO申报，但2025年2月主动撤回。随后济人药业便启动了北 交所上市辅导、申报新三板挂牌等相关工作。不到一年，济人药业IPO申请被北交所受理。 2023年、2024年，济人药业实现营业收入分别约为11.34亿元、12.30亿元，实现归母净利润分别约为 1.31亿元、1.32亿元。 本次IPO，济人药业选择的是北交所第一套上市标准，即预计市值不低于2亿元，最近两年净利润均不 低于1500万元且加权平均净资产收益率平均不低于8%，或者最近一年净利润不低于2500万元且加权平 均净资产收益率不低于8%。 济人药业拟募资金额约为5.26亿元，主要用于"年产450吨中药配方颗粒项目""年产8000吨中药饮片项 目""研发中心建设项目""营销网络建设项目"及"补充流动资金"。 济人药业是一家中药药企，主要产品包括中成药、中药饮片、中药配方颗粒三大类。已被录入甲型 H1N1流感、人感染H7N9禽流感、新冠病毒感染等疾病中成药诊疗方案的疏 ...

Core Viewpoint - Jiren Pharmaceutical is advancing its IPO process after transitioning from the Shanghai Stock Exchange to the Beijing Stock Exchange, with a focus on its core product, Shufeng Jiedu Capsule, which is included in treatment plans for various viral infections [1][2]. Company Overview - Jiren Pharmaceutical, established in April 2001, has developed into a modern Chinese medicine manufacturer integrating standardized planting of medicinal materials, production, and sales of traditional Chinese medicine [6]. - The company has ventured into the financial sector by holding a 0.18% stake in Bozhou Yaodu Rural Commercial Bank since 2018 [6]. Product Information - Shufeng Jiedu Capsule is a proprietary product of Jiren Pharmaceutical, primarily used for treating upper respiratory infections and various viral diseases [2]. - The market share of Shufeng Jiedu Capsule is currently 4.24%, ranking third among cold medicine brands, following Yiling Pharmaceutical's Lianhua Qingwen Granules and Haitai Pharmaceutical's Sijikang Antiviral Mixture [3][2]. Financial Performance - Jiren Pharmaceutical reported revenues of approximately CNY 1.134 billion and CNY 1.230 billion for 2023 and 2024, respectively, with net profits of CNY 131 million and CNY 132 million [6]. - Sales revenue for Shufeng Jiedu Capsule is projected to decline, with expected revenues of CNY 475 million in 2023 and CNY 377 million in 2024 [3][4]. Regulatory Scrutiny - The National Equities Exchange and Quotations (NEEQ) has raised concerns regarding the high academic promotion costs for Shufeng Jiedu Capsule despite its long-standing inclusion in medical insurance, as well as the effectiveness of measures to isolate commercial bribery risks between the company and its promoters [1][5]. - Jiren Pharmaceutical has engaged 299 and 273 promoters for academic promotion in 2023 and 2024, respectively, and has conducted visits to over 590,000 and 536,000 individuals in relevant medical departments [5].

IPO Pipeline Overview - As of August 10, there are 299 companies in the IPO pipeline, with 29 on the Shanghai Main Board, 36 on the Sci-Tech Innovation Board, 26 on the Shenzhen Main Board, 29 on the ChiNext, and 179 on the Beijing Stock Exchange [1][2]. Newly Listed Companies - From August 4 to August 10, three companies were newly listed: - Hansan (Nanjing) Technology Co., Ltd. on the ChiNext with a closing price of 82.89 CNY per share, a rise of 186.72%, and a trading volume of 2.048 billion CNY [4][5]. - Yangzhou Tianfulong Group Co., Ltd. on the Shanghai Main Board with a closing price of 56.80 CNY per share, a rise of 140.68%, and a trading volume of 1.971 billion CNY [5]. - Jiangsu Youli Intelligent Equipment Co., Ltd. on the Beijing Stock Exchange with a closing price of 83.22 CNY per share, a rise of 246.89%, and a trading volume of 732 million CNY [5]. New Counseling Record Companies - Eight companies were newly recorded for counseling from August 4 to August 10, including: - Beijing Jichuang Beifang Technology Co., Ltd., focusing on integrated circuit design [6][7]. - Yao Mazi Food Co., Ltd., specializing in seasoning products [8]. - Changde New Material Technology Co., Ltd., engaged in resource utilization and new materials [8]. - Anhui Jiren Pharmaceutical Co., Ltd., focusing on modern traditional Chinese medicine [8]. - Dongguan Yuanli Optoelectronics Co., Ltd., specializing in LCD backlight modules [8]. - Zhongdao Optoelectronic Equipment Co., Ltd., focusing on detection equipment for displays and solar cells [8]. - Tianbo Intelligent Technology (Shandong) Co., Ltd., producing various automotive sensors [9]. - Zhongxing Micro Technology Co., Ltd., providing video technology solutions based on AI and big data [9]. Approval Status of Companies - Three companies successfully passed the review process from August 4 to August 10: - Zhongcheng Zhixin Engineering Consulting Group Co., Ltd. on the Beijing Stock Exchange [10]. - Suzhou Fengbei Biotechnology Co., Ltd. on the Shanghai Main Board [10]. - Zhuhai Nante Metal Technology Co., Ltd. on the Beijing Stock Exchange [10]. - The review for Jiejia Robot Co., Ltd. was canceled [10]. Registration Approval - Two companies received registration approval from August 4 to August 10: - Guangzhou Bibete Pharmaceutical Co., Ltd., focusing on innovative drug development [16][17]. - Daming Electronics Co., Ltd., specializing in automotive electronic components [18]. Termination of Review - Only one company, Wenduoli Sunshade Materials (Dezhou) Co., Ltd., withdrew its IPO application during this period [20][21].